NEEDHAM, Mass. and PALM BEACH GARDENS, Fla., Jan. 5, 2016 /PRNewswire/ -- Xcovery, a developer of targeted therapeutics for ALK+ non-small cell lung cancer (NSCLC) is scheduled to present January 6th, 2016 at the fourth annual AACR-IASLC International Joint Conference: Lung Cancer Translational Science from the Bench to the Clinic, at the Hard Rock Hotel, in San Diego, CA. Dr. Karen L. Reckamp, Associate Professor at the City of Hope Comprehensive Cancer Center will present the poster titled "Phase l/ll trial of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK+ non-small cell lung cancer (NSCLC)."
Session Information:
Date: January 6, 2016 12:30-2:30
Location: Encore, Abbey Road and Penny Lane rooms
Poster Number: B21
About X-396
X-396, a small molecule ALK inhibitor, is being investigated for the treatment of ALK+ NSCLC, lymphoma and neuroblastoma. X-396 has been validated in potency and selectivity assays that demonstrate it is more selective and up to 10 times more potent than competitive ALK inhibitors tested. X-396 has also shown activity in some ALK mutations that suggest resistance to other small molecule ALK inhibitors. X-396 is currently enrolling patients in a Phase II human clinical trial.
About Non-Small Cell Lung Cancer and ALK
Lung cancer is the second most common type of cancer identified in the United States with an estimated 221,000 new diagnoses expected in 2015. Non-small cell lung cancer is the most common type of lung cancer, accounting for an estimated 85-90% of the lung cancer cases.
About Xcovery
Xcovery is a biopharmaceutical company working to improve the lives of patients with cancer by discovering medicines to fight advanced tumors. Xcovery is developing a pipeline of oncology therapies to target a wide range of advanced tumors. For more information, visit www.xcovery.com
Forward-Looking Statements
This press release contains forward-looking statements that are based on company management's current beliefs and expectations and are subject to currently unknown information, risks and circumstances and actual results may vary from what is being currently projected.
Corporate Contact:
Teri Swift
Xcovery Corporate Communications
(561) 727-9559
teri@xcovery.com
Logo - http://photos.prnewswire.com/prnh/20151228/318197LOGO
SOURCE Xcovery